Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25880792 | 0.80 | ENPP1 (0.43) | TDP1MAPTL3MBTL1HPGDRAB9A | |
| SCHEMBL29549805 | 0.76 | ALDH1A1 (0.41) | TDP1MAPTL3MBTL1HPGDMAPK1 | |
| SCHEMBL23530022 | 0.76 | ALDH1A1 (0.41) | TDP1MAPTL3MBTL1HPGDMAPK1 | |
| SCHEMBL25880866 | 0.75 | TDP1 (0.36) | TDP1 | |
| SCHEMBL25880892 | 0.75 | TDP1 (0.36) | TDP1L3MBTL1MAPK1 | |
| SCHEMBL20839734 | 0.75 | PLAU (0.41) | TDP1MAPTL3MBTL1HPGDMAPK1 | |
| SCHEMBL30042712 | 0.73 | TDP1 (0.35) | TDP1 | |
| SCHEMBL30936658 | 0.73 | TDP1 (0.38) | TDP1 | |
| SCHEMBL22445196 | 0.73 | TDP1 (0.38) | TDP1 | |
| SCHEMBL2767989 | 0.73 | TDP1 (0.38) | TDP1L3MBTL1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227474-A1 | COMPOSITIONS AND METHODS FOR CORRECTION OF ABERRANT SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230227474-A1 | COMPOSITIONS AND METHODS FOR CORRECTION OF ABERRANT SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227474-A1 | COMPOSITIONS AND METHODS FOR CORRECTION OF ABERRANT SPLICING | RBM17, SF3B1, SF3B5 | TDP1 387/4885MAPT 2406/4885L3MBTL1 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.